Investors in Life Sciences

Sciety was started in 2016 by a founding team with diverse backgrounds in physics, business, medicine and finance. Since our start, we have invested over 1 billion SEK in 25 companies, whereof 8 companies have been successfully acquired or listed on the stock exchange. We are based in Stockholm, but travel across the Nordics to meet with leading ventures and investors.

Almi Invest is renowned as Sweden's leading investor in startups, operating through eight regional VC funds and one national Green Tech fund across the country. Managing a substantial equity pool of SEK 3.5 billion, Almi Invest has backed approximately 660 startups since its inception. The company's successful investments have resulted in acquisitions by major industry giants like Google, Apple, Microsoft, and Qlik, as well as through IPOs. Almi Invest operates as a venture capital firm within the Almi Group, supported by the European Regional Development Fund, Almi, Almi Invest, and regional stakeholders.

Granitor specializes in investing in cutting-edge technologies with significant commercial potential and global relevance. Primarily focused on Swedish companies, Granitor supports innovations in solar-powered water purification, sustainable food production, environmentally neutral energy solutions, zero-emissions transportation, and breakthrough medicines for previously untreatable diseases. By making early investments and maintaining a long-term commitment, Granitor aims to propel sustainable innovations forward, bridging the gap to market adoption. The firm's philosophy emphasizes active engagement and strategic leadership, playing a pivotal role in the operational and strategic development of its portfolio companies.

HealthCap is a European venture capital firm investing globally in life sciences and has raised eight funds since 1996. HealthCap has backed and built more than 127 companies, taken more than 45 companies public, and completed numerous trade sales. The investment strategy focuses on diseases with a high unmet medical need and breakthrough therapies that have the potential to be transformative, change clinical practice, and change the lives of patients suffering from these conditions.

Trill Impact operates as a dedicated Impact House focused exclusively on impact investments. Their unique design ensures that all investments are aimed at generating positive returns while making significant impacts on people, the planet, and investors alike.

Bonit Capital, a Swedish family-owned investment company, engages in diverse sectors and asset classes, including social investments and outcome models. In Venture Capital, Bonit focuses on life sciences, providing capital and industry expertise to ambitious founders in digital health, medical technology, and diagnostics.

Crosslight Partners tackles substantial challenges within the food system with innovative solutions. These companies are at the early growth stage, demonstrating commercial traction. Investments typically range from SEK 1 to 10 million, with flexible ownership stakes. While the focus is global, emphasis lies on the Nordics and Europe. The investment horizon spans 3 to 7 years, and governance involvement includes securing a board seat or holding quarterly follow-up meetings.

The Nordic region is at the forefront of the technology and scientific revolution. Northislet's vision is to help create and build Nordic champions within Life Science, allowing them to grow and reach their potential in the hands of local entrepreneurs, employees, and shareholders. Their goal is to create long-term value for all stakeholders, fostering a prosperous environment for new and existing companies, entrepreneurs, and scientists, making the Nordic region a competitive and attractive place for global talent within Life Science. Northislet aims to become a leading Nordic investment company in Life Science over the next 25 years, with the journey just beginning.

Ysios Capital, a leading Spanish venture capital firm, provides private equity financing to early and mid-stage life science companies that develop disruptive therapeutic products and platform technologies. Founded in 2008, Ysios Capital manages over USD 420M through three dedicated funds in life sciences and is led by a team of professionals experienced in building biotech companies.

Seed Capital de Bizkaia aims to promote and develop new or existing companies that seeks to develop socially innovative projects. SEED CAPITAL BIZKAIA, Sociedad Gestora de Entidades de Inversión de Tipo Cerrado SA (SGEIC) is a Public Company attached to the Department of Economic Promotion of the Provincial Council of Bizkaia, dedicated to the administration and management of various financing instruments. Founded in 1989, Seed Capital Bizkaia has been firmly committed to promoting innovation, social impact and the promotion and regeneration of the business fabric in Bizkaia for more than 30 years.